US › Healthcare

Veradermics, Incorporated (MANE)

US · Healthcare · Biotechnology

$107.28+5.29%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-27.2M
EPS
$-0.73
EPS estimate
$-0.85

EPS came in at -0.73 against a street estimate of -0.85 — a beat of 14.2%.

Key statistics

Market cap
$4.26B
Forward P/E
0.0
P/B
11.23
Book value
$10.46
EPS (TTM)
$-2.65
52-week high
$131.24
52-week low
$32.00
50-day MA
$107.57
200-day MA
$83.64

Analyst view

with an average price target of $163.50.

Shareholding

Insiders
2.74%
Institutions
80.21%

Largest institutional holders

FundStake
Suvretta Capital Management, LLC9.98%
SR ONE CAPITAL MANAGEMENT, LP5.75%
Citadel Advisors Llc4.37%
FMR Inc4.29%
Viking Global Investors LP4.05%
Siren, L.L.C.3.60%
Adage Capital Partners Gp LLC2.63%
Aberdeen Group PLC2.52%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Veradermics, Incorporated — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.